Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Melanocortin Receptor 4 (MC4R) Treatment Pipeline Review H2 2016

Wednesday, October 26, 2016 4:04
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Melanocortin Receptor 4 (MC4R) – Pipeline Review, H2 2016’, provides in depth analysis on Melanocortin Receptor 4 (MC4R) targeted pipeline therapeutics.

The report provides comprehensive information on the Melanocortin Receptor 4 (MC4R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development and features dormant and discontinued projects.

Request a sample report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R) 
- The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scop

Complete report details @

Key points in table of content

Table of Contents 2 
List of Tables 5 
List of Figures 5 
Introduction 6 
Report Coverage 6 
Melanocortin Receptor 4 (MC4R) Overview 7 
Therapeutics Development 8 
Melanocortin Receptor 4 (MC4R) – Products under Development by Stage of Development 8 
Melanocortin Receptor 4 (MC4R) – Products under Development by Therapy Area 9 
Melanocortin Receptor 4 (MC4R) – Products under Development by Indication 10 
Melanocortin Receptor 4 (MC4R) – Pipeline Products Glance 11 
Late Stage Products 11 
Early Stage Products 12 
Unknown Stage Products 13 
Melanocortin Receptor 4 (MC4R) – Products under Development by Companies 14 
Melanocortin Receptor 4 (MC4R) – Products under Development by Universities/Institutes 16 
Melanocortin Receptor 4 (MC4R) – Therapeutics Assessment 18 
Assessment by Monotherapy/Combination Products 18 
Assessment by Mechanism of Action 19 
Assessment by Route of Administration 21 
Assessment by Molecule Type 23 
Melanocortin Receptor 4 (MC4R) – Companies Involved in Therapeutics Development 25 
AstraZeneca Plc 25 
Mallinckrodt Plc 26 
Obexia AG 27 
Palatin Technologies, Inc. 28 
Pfizer Inc. 29 
Retrophin Inc. 30 
Melanocortin Receptor 4 (MC4R) – Drug Profiles 31 
(liraglutide + setmelanotide) – Drug Profile 31 
Product Description 31 
Mechanism Of Action 31 
R&D Progress 31 
AQB-565 – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
bremelanotide – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
corticotropin – Drug Profile 38 
Product Description 38 
Mechanism Of Action 38 
R&D Progress 38 
cosyntropin – Drug Profile 40 
Product Description 40 
Mechanism Of Action 40 
R&D Progress 40 
OBX-1201 – Drug Profile 41 
Product Description 41 
Mechanism Of Action 41 
R&D Progress 41 
PL-8905 – Drug Profile 42 
Product Description 42 
Mechanism Of Action 42 
R&D Progress 42 
Proteins to Agonize MC4R for Obesity – Drug Profile 43 
Product Description 43 
Mechanism Of Action 43 
R&D Progress 43 
setmelanotide – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
Small Molecules to Agonize MC4-R for Obesity – Drug Profile 47 
Product Description 47 
Mechanism Of Action 47 
R&D Progress 47 
Small Molecules to Target Melanocortin-4 Receptor for Cachexia – Drug Profile 48 
Product Description 48 
Mechanism Of Action 48 
R&D Progress 48 
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction – Drug Profile 49 
Product Description 49 
Mechanism Of Action 49 
R&D Progress 49 
Melanocortin Receptor 4 (MC4R) – Dormant Projects 50 
Melanocortin Receptor 4 (MC4R) – Discontinued Products 52 
Melanocortin Receptor 4 (MC4R) – Featured News & Press Releases 53 
Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder 53 
Jul 20, 2016: Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity 53 
Jul 05, 2016: Health Care Resource Use and Costs of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse 54 
Jun 30, 2016: Catalent Announces Agreement To Commercially Supply Palatin Technologies’ New Bremelanotide Female Sexual Dysfunction Product In Pen Injectors 55 
Jun 09, 2016: Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus 56 
Jun 06, 2016: Palatin Technologies Receives U.S. Patent Strengthening Its Melanocortin Peptide Intellectual Property 57 
May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome 58 
Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting 58 
Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction 59 
Jan 07, 2016: Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity 59 
Jan 07, 2016: Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome 60 
Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction 60 
Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus 60 
Nov 06, 2015: Rhythm Presents Cardiovascular Safety Data from Phase 1b/2a Clinical Trials of Setmelanotide in Obesity 62 
Nov 06, 2015: Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity 62 
Appendix 64 
Methodology 64 
Coverage 64 
Secondary Research 64 
Primary Research 64 
Expert Panel Validation 64 
Contact Us 64 
Disclaimer 65

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.